Stay updated with breaking news from Alimera Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research note published on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. Other research analysts have also issued reports about the company. HC Wainwright reaffirmed a buy rating and issued a $9.00 price objective on shares […]
HC Wainwright reaffirmed their buy rating on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a report published on Monday morning, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Alimera Sciences’ Q1 2023 earnings at ($0.58) EPS, Q2 2023 earnings at ($0.30) […]
Alimera Sciences (NASDAQ: ALIM) has recently received a number of price target changes and ratings updates: 4/3/2023 – Alimera Sciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock. 4/3/2023 – Alimera Sciences had its price target lowered by analysts at Craig Hallum from […]
Operator: Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences 2022 Financial Results Conference Call.
Craig Collard Appointed CEOAdam Morgan Named Chairman of the BoardSAN DIEGO, April 3, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX)...